
ABR-238901
CAS No. 1638200-22-2
ABR-238901( —— )
Catalog No. M35093 CAS No. 1638200-22-2
ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 190 | Get Quote |
![]() ![]() |
5MG | 297 | Get Quote |
![]() ![]() |
10MG | 472 | Get Quote |
![]() ![]() |
25MG | 725 | Get Quote |
![]() ![]() |
50MG | 994 | Get Quote |
![]() ![]() |
100MG | 1332 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameABR-238901
-
NoteResearch use only, not for human use.
-
Brief DescriptionABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).
-
DescriptionABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research.
-
In Vitro——
-
In VivoAnimal Model:C57BL/KaLwRij mice with 5T33MMvv cells Dosage:30 mg/kg Administration:Gavage; daily; for 3 weeks Result:Caused less angiogenesis.Caused less IL6 and IL10 in myeloid-derived suppressor cells (MDSCs).
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetTLR
-
RecptorTLR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1638200-22-2
-
Formula Weight394.63
-
Molecular FormulaC11H9BrClN3O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 33.33 mg/mL (84.46 mM; Ultrasonic (<60°C); H2O : < 0.1 mg/mL (insoluble)
-
SMILESCOc1ncc(cc1Br)S(=O)(=O)Nc1cncc(Cl)c1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kim De Veirman, et al. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res. 2017 Oct;5(10):839-846.?
molnova catalog



related products
-
IAXO-102
IAXO-102 is a TLR4 antagonist that negatively regulates TLR4 signaling.
-
CU-CPT-8m
CU-CPT-8m is an toll-like receptor 8 (TLR8) antagonist (IC50 : 67 nM).
-
EPZ020411 2HCl
EPZ020411 is an effective and specific small molecule PRMT6 inhibitor (IC50=10 nM).